NUVB News and Press, Nuvation Bio Inc. Class A From 03/26/24

2024-03-26 07:00:03 ET Kaveri Pohlman from BTIG issued a price target of $5.00 for NUVB on 2024-03-26 05:37:00. The adjusted price target was set to $5.00. At the time of the announcement, NUVB was trading at $2.25. The overall price target consensus is at $8.00 with hig...

2024-03-25 10:00:59 ET More on Health Care Select Sector SPDR XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run Johnson & Johnson, Boston Scientific least shorted stocks in S&...

A look at the top 10 most actives in the United States Next.e.GO N.V. (EGOX) rose 90.8% to $0.075 on volume of 125,000,352 shares Fisker Inc. Class A (FSR) fell 28.2% to $0.08965 on volume of 60,620,440 shares Lucid Group Inc. (LCID) rose 17.3% to $3.2489 on volume of 33,193,462 shares ...

2024-03-25 09:01:13 ET More on Nuvation Bio Seeking Alpha’s Quant Rating on Nuvation Bio Historical earnings data for Nuvation Bio Financial information for Nuvation Bio Read the full article on Seeking Alpha For further details see: Nuvati...

Acquisition transforms Nuvation Bio into late-stage global oncology company with potential to become a commercial organization by the end of 2025 Acquisition adds taletrectinib, a next-generation, potentially best-in-class ROS1 inhibitor with Breakthrough Therapy Designations currently co...

NUV-1511 is the Company’s first drug-drug conjugate (DDC) to enter the clinic Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced that the ...

2024-03-14 08:45:28 ET FN Media Group Presents USA News Group News Commentary Vancouver, BC – March 14, 2024 – USA News Group – Known as one of the most deadly forms of cancer, pancreatic cancer still has the highest mortality rate of all m...

Determined maximum tolerated dose (MTD) in Phase 1 monotherapy study of NUV-868; Phase 1b studies of NUV-868 in combination with olaparib or enzalutamide remain ongoing Received U.S. Food and Drug Administration (FDA) clearance of Investigational New Drug (IND) application for NUV-1511, t...

2024-02-09 22:17:09 ET Summary David Abrams' 13F portfolio value increased from $3.03B to $3.22B this quarter. Meta Platforms and Teva Pharmaceutical saw stake decreases in Abrams' portfolio. Abrams kept steady positions in Lithia Motors, Asbury Automotive, Alphabet Inc., and ...

2024-01-08 16:39:14 ET More on Nuvation Bio Seeking Alpha’s Quant Rating on Nuvation Bio Historical earnings data for Nuvation Bio Financial information for Nuvation Bio For further details see: FDA clears Nuvation to begin Phase 1/2 study for onco...